Hurd YL, et al. - In this exploratory double-blind randomized placebo-controlled trial performed with drug-abstinent individuals with heroin use disorder, researchers examined cannabidiol (CBD), a nonintoxicating phytocannabinoid, for its potential to lower cue-induced craving and anxiety, which often contribute to relapse and continued drug use. Compared to placebo, acute CBD administration led to a significant reduction in both craving and anxiety induced by the presentation of salient drug cues vs neutral cues. Seven days following the final short-term (3-day) CBD exposure, significant protracted effects of CBD on these measures remained. In addition, drug cue-induced physiological measures of heart rate and salivary cortisol levels were lowered among those who received CBD. These findings provide a firm basis for further examination of CBD as a treatment for opioid use disorder.